EN PL
PRACA ORYGINALNA
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Introduction:
The aims were to study the sociodemographic characteristics of patients presenting to the clinic and to study the clinical and serological pattern of systemic lupus erythematosus (SLE) in a new rheumatology clinic of a predominantly Yoruba population.

Material and methods:
This was a retrospective, cross-sectional study conducted over 7 years (January 2017 – December 2023). Patients who satisfied the 1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria were enrolled using their medical records. Patients with overlap syndromes and other inflammatory or noninflammatory rheumatic diseases were excluded from the study. Their sociodemographic, clinical, laboratory, and treatment data were retrieved from their medical records and analysed using IBM SPSS version 23.0 software.

Results:
A total of 65 patients were diagnosed with SLE with a frequency of 15.8%. The mean age ±SD of the patients at presentation was 33.85 years ±11.01 and the female to male ratio was 9.8 : 1. The median (IQR) duration of symptoms at presentation was 7.0 months (3–24). The common clinical presentations included synovitis (86.2%), acute cutaneous rash (53.8%), oral ulcers (52.3%), nonscarring alopecia (50.8%), and serositis (47.7%). Proteinuria was seen in 37.7% of the patients and the predominant renal histopathological feature was Class IV. Antinuclear antibody was 100% positive with 50.94% of the patients having a titre of 1 : 5,120 and above. Anti- double-stranded deoxyribonucleic acid and anti-Smith antibodies each had 50% prevalence. Dyslipidaemia was found in 76.7% of the patients.

Conclusions:
The study’s findings are largely consistent with similar studies done in Africa. Further prospective multi-centred studies are needed to further determine the epidemiological characteristics of the disease in Nigeria with a multi-ethnic population.

 
REFERENCJE (40)
1.
Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2018; 32: 188–205, DOI: 10.1016/j.berh.2018.09.004.
 
2.
Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun 2019; 96: 1–13, DOI: 10.1016/j.jaut.2018.11.001.
 
3.
Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford) 2017; 56: 1945–1961, DOI: 10.1093/rheumatology/kex260.
 
4.
Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemio- logy of systemic lupus erythematosus. Nat Rev Rheumatol 2021; 17: 515–532, DOI: 10.1038/s41584-021-00668-1.
 
5.
Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-speci- fic mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 2016; 25: 727–734, DOI: 10.1177/ 0961203315627202.
 
6.
Yen EY, Singh RR. Brief report: Lupus – an unrecognized leading cause of death in young females: A population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol 2018; 70: 1251–1255, DOI: 10.1002/art.40512.
 
7.
Greenwood BM. Autoimmune disease and parasitic infections in Nigerians. Lancet 1968; 2: 380–382, DOI: 10.1016/ s0140-6736(68)90595-3.
 
8.
Essouma M, Nkeck JR, Endomba FT, et al. Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. J Autoimmun 2020; 106: 102348, DOI: 10.1016/j.jaut.2019.102348.
 
9.
Adelowo O, Mody GM, Tikly M, et al. Rheumatic diseases in Africa. Nat Rev Rheumatol 2021; 17: 363–374, DOI: 10.1038/s41584-021-00603-4.
 
10.
Osaze O, Olaosebikan HB, Yerima A, et al. Pattern of systemic lupus erythematosus in NIGERIA: a multicentre descriptive hospital-based study. Clin Rheumatol 2023; 42: 2787–2797, DOI: 10.1007/s10067-023-06672-y.
 
11.
Adelowo OO, Oguntona SA. Pattern of systemic lupus erythematosus among Nigerians. Clin Rheumatol 2009; 28: 699–703, DOI: 10.1007/s10067-009-1139-6.
 
12.
Emorinken A, Dic-Ijiewere MO, Erameh CO, et al. Clinical and laboratory profile of systemic lupus erythematosus patients at a rural tertiary centre in South-South Nigeria: experience from a new rheumatology clinic. Reumatologia 2021; 59: 402–410, DOI: 10.5114/reum.2021.111714.
 
13.
Symmons DP. Frequency of lupus in people of African origin. Lupus 1995; 4: 176–178, DOI: 10.1177/096120339500400303.
 
14.
Cervera R, Khamashta MA, Font J, et al. Systemic lupus eryt- hematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72: 113–124.
 
15.
Ahmed N, Shigidi M, Al Agib AN, et al. Clinical features and antinuclear antibodies profile among adults with systemic lupus erythematosus and lupus nephritis: a cross-sectional study. Pan Afr Med J 2017; 27: 114, DOI: 10.11604/pamj.2017.27.114.5981.
 
16.
Genga EK, Shiruli BC, Odhiambo J, et al. Clinical characteristics of patients with systemic lupus erythematosus in Nairobi, Kenya. Afr J Rheumatol 2015; 3: 62–66.
 
17.
Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009; 18: 465–473, DOI: 10.1177/0961203308100660.
 
18.
Wadee S, Tikly M, Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46: 1487–1491, DOI: 10.1093/ rheumatology/kem180.
 
19.
Kamen DL, Barron M, Parker TM, et al. Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 2008; 58: 1237–1247, DOI: 10.1002/art.23416.
 
20.
Tomczyk-Socha M, Sikorska-Szaflik H, Frankowski M, et al. Clinical and immunological characteristics of Polish patients with systemic lupus erythematosus. Adv Clin Exp Med 2018; 27: 57–61, DOI: 10.17219/acem/65860.
 
21.
Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016; 12: 605–620, DOI: 10.1038/nrrheum.2016.137.
 
22.
Bortolini MFF, Pereira VP, Gomes Dos Santos TA, et al. Systemic lupus erythematosus in children and adults: A retrospective study in Brazilian patients. Lupus 2021; 30: 1197–1202, DOI: 10.1177/09612033211010330.
 
23.
Hejazi EZ, Werth VP. Cutaneous lupus erythematosus: An update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol 2016; 17: 135–146, DOI: 10.1007/s40257-016-0173-9.
 
24.
Zian Z, Maamar M, Aouni ME, et al. Immunological and clinical characteristics of systemic lupus erythematosus: A series from Morocco. Biomed Res Int 2018; 2018: 3139404, DOI: 10.1155/2018/3139404.
 
25.
Gbané-Koné M, Ouattara B, Djaha KJM, et al. Autoantibodies in systemic lupus erythematosus, on Black African subject, in Abidjan. Open J Rheumatol Autoimmune Dis 2015; 5: 28–35, DOI: 10.4236/ojra.2015.52006.
 
26.
Elbagir S, Elshafie AI, Elagib EM, et al. Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. Rheumatology (Oxford) 2020; 59: 968–978, DOI: 10.1093/rheumatology/kez323.
 
27.
Alarcon GS, McGwin G, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11: 95–101, DOI: 10.1191/0961203302lu155oa.
 
28.
Unterman A, Nolte JES, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011; 41: 1–11, DOI: 10.1016/ j.semarthrit.2010.08.001.
 
29.
Teh CL, Ling GR, Aishah WS. The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. Rheumatol Int 2015; 35: 153–157. DOI: 10.1007/s00296-014-3057-4.
 
30.
Saleh M, Eltoraby EE, Tharwat S, et al. Clinical and histopathological features and short-term outcomes of lupus nephritis: a prospective study of 100 Egyptian patients. Lupus 2020; 29: 993–1001, DOI: 10.1177/0961203320928424.
 
31.
Kosałka-Węgiel J, Dziedzic R, Siwiec-Koźlik A, et al. Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: A single-centre retrospective study. Rheumatol Int 2024, DOI: 10.1007/s00296-024-05579-4.
 
32.
Mody PG, Mody GM, Assounga A. The clinical manifestations and response to treatment in South Africans with lupus nephritis. Lupus 2018; 27: 1207–1217, DOI: 10.1177/0961203318770024.
 
33.
Dima A, Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus 2016; 25: 1173–1179. DOI: 10.1177/0961203316651742.
 
34.
Li H, Zheng Y, Chen L, Lin S. High titers of antinuclear antibody and the presence of multiple autoantibodies are highly suggestive of systemic lupus erythematosus. Sci Rep 2022; 12: 1687, DOI: 10.1038/s41598-022-05807-6.
 
35.
Adelowo OO, Ojo O, Oduenyi I. Auto antibodies in Nigerian lupus patients. Afr J Med Med Sci 2012; 41: 177–181.
 
36.
Tikly M, Burgin S, Mohanlal P, et al. Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol 1996; 15: 261–265. DOI: 10.1007/BF02229704.
 
37.
Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res 2017; 65: 543–550. DOI: 10.1007/s12026-016-8892-9.
 
38.
Tselios K, Koumaras C, Gladman DD, et al. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum 2016; 45: 604–610, DOI: 10.1016/ j.semarthrit.2015.10.010.
 
39.
Akintayo RO, Akpabio AA, Kalla AA, et al. The impact of COVID-19 on rheumatology practice across Africa. Rheumato- logy (Oxford) 2021; 60: 392–398, DOI: 10.1093/rheumatology/keaa600.
 
40.
Adelowo OO, Olisa O, Asekhame OT, et al. Biotherapies in medical practice: A review and the Nigerian experience. West Afr J Med 2021; 38: 486–493.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top